



# GEORGIA

Number of new cases

**13 689**

Number of deaths


**8 459**

Number of prevalent cases (5-year)

**37 912**


## Statistics at a glance, 2022

	Males	Females	Both sexes
<b>Population</b>	1 890 252	2 078 476	3 968 728
<b>Incidence*</b>			
Number of new cancer cases	7 253	6 436	13 689
Age-standardized incidence rate	246.8	165.5	197.5
Risk of developing cancer before the age of 75 years (cum. risk %)	26.2	16.9	20.8
Top 3 leading cancers (ranked by cases)**	Lung Prostate Colorectum	Breast Colorectum Corpus uteri	Breast Lung Colorectum
<b>Mortality*</b>			
Number of cancer deaths	4 636	3 823	8 459
Age-standardized mortality rate	151.7	84.5	111.7
Risk of dying from cancer before the age of 75 years (cum. risk %)	16.6	9.1	12.3
Top 3 leading cancers (ranked by deaths)**	Lung Prostate Colorectum	Breast Colorectum Ovary	Lung Breast Colorectum
<b>Prevalence*</b>			
5-year prevalent cases	18 640	19 272	37 912



## Top 5 most frequent cancers\*\*


**Males**



Rank	Cancer site	Number of cases	Percent
1st	Lung	1 363	18.8%
2nd	Prostate	1 090	15.0%
3rd	Colorectum	605	8.3%
4th	Bladder	476	6.6%
5th	Stomach	441	6.1%
-	Others	3 278	45.2%

Number of new cases in 2022, males, all ages


**Females**



Rank	Cancer site	Number of cases	Percent
1st	Breast	1 730	26.9%
2nd	Colorectum	520	8.1%
3rd	Corpus uteri	418	6.5%
4th	Ovary	390	6.1%
5th	Cervix uteri	330	5.1%
-	Others	3 048	47.4%

Number of new cases in 2022, females, all ages

**Both sexes**



Rank	Cancer site	Number of cases	Percent
1st	Breast	1 730	12.6%
2nd	Lung	1 572	11.5%
3rd	Colorectum	1 125	8.2%
4th	Prostate	1 090	8.0%
5th	Stomach	759	5.5%
-	Others	7 413	54.2%

Number of new cases in 2022, both sexes, all ages

Incidence, Mortality and Prevalence by cancer site

Cancer	New cases				Deaths				5-year prevalence	
	Number	Rank	(%)	Cum.risk	Number	Rank	(%)	Cum.risk	Number	Prop. (per 100 000)
Breast	1 730	1	12.6	5.4	861	2	10.2	2.3	6 680	17.6
Lung	1 572	2	11.5	2.8	1 317	1	15.6	2.3	2 021	5.3
Colorectum	1 125	3	8.2	1.8	649	3	7.7	0.92	3 384	8.9
Prostate	1 090	4	8.0	4.7	482	5	5.7	1.4	4 139	10.9
Stomach	759	5	5.5	1.2	569	4	6.7	0.85	1 072	2.8
Bladder	556	6	4.1	0.92	314	8	3.7	0.41	1 791	4.7
Liver	476	7	3.5	0.80	416	6	4.9	0.69	600	1.6
Pancreas	419	8	3.1	0.66	384	7	4.5	0.60	387	1.0
Corpus uteri	418	9	3.1	1.4	192	14	2.3	0.54	1 566	4.1
Brain CNS	403	10	2.9	0.69	307	9	3.6	0.51	1 567	4.1
Ovary	390	11	2.8	1.3	261	11	3.1	0.80	1 145	3.0
Cervix uteri	330	12	2.4	1.1	210	13	2.5	0.64	1 071	2.8
Leukaemia	315	13	2.3	0.53	267	10	3.2	0.44	957	2.5
Melanoma	302	14	2.2	0.49	84	18	0.99	0.11	1 074	2.8
Larynx	297	15	2.2	0.55	233	12	2.8	0.42	993	2.6
NHL	297	15	2.2	0.55	160	16	1.9	0.27	1 020	2.7
Kidney	288	17	2.1	0.54	167	15	2.0	0.29	911	2.4
Thyroid	244	18	1.8	0.48	41	22	0.49	0.06	882	2.3
Lip, oral cavity	208	19	1.5	0.35	107	17	1.3	0.18	617	1.6
Testis	132	20	0.96	0.47	27	27	0.32	0.10	510	1.3
Hodgkin lymphoma	105	21	0.77	0.19	30	25	0.36	0.05	379	1.0
Gallbladder	93	22	0.68	0.14	75	20	0.89	0.11	117	0.31
Oesophagus	87	23	0.64	0.13	79	19	0.93	0.12	112	0.30
Multiple myeloma	70	24	0.51	0.14	62	21	0.73	0.12	213	0.56
Hypopharynx	67	25	0.49	0.13	30	25	0.36	0.05	141	0.37
Vulva	63	26	0.46	0.14	34	24	0.40	0.06	179	0.47
Oropharynx	45	27	0.33	0.09	36	23	0.43	0.07	127	0.34
Salivary glands	36	28	0.26	0.04	22	29	0.26	0.03	105	0.28
Nasopharynx	35	29	0.26	0.06	26	28	0.31	0.05	106	0.28
Penis	28	30	0.21	0.13	14	30	0.17	0.06	90	0.24
Vagina	16	31	0.12	0.03	9	32	0.11	0.01	38	0.10
Mesothelioma	13	32	0.10	0.02	12	31	0.14	0.02	16	0.04
<b>All cancers</b>	<b>13 689</b>	-	-	<b>20.8</b>	<b>8 459</b>	-	-	<b>12.3</b>	<b>37 912</b>	-
<b>All cancers excl. NMSC</b>	<b>13 184</b>	-	-	<b>20.4</b>	<b>8 238</b>	-	-	<b>12.2</b>	<b>36 299</b>	-

## Data source and methods

### Incidence



**Country-specific data source:** No data  
**Method:** Estimated from national mortality estimates by modelling, using mortality:incidence ratios derived from survival estimation

### Mortality

**Country-specific data source:** National (WHO)  
**Method:** National rates projected to 2022

### Prevalence

Computed using sex-, site- and age-specific incidence to 1-,3- and 5-year prevalence ratios from Nordic countries for the period (2011-2020), and scaled using Human Development Index (HDI) ratios.



\* includes non-melanoma skin cancer (NMSC)

\*\* NMSC included in other cancers

Age standardization using world population ([see link](#))

## References

### Website citation

Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2024). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: <https://gco.iarc.who.int/today>, accessed [DD Month YYYY].

### Cancer incidence and mortality data

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021 Feb 4. doi: 10.3322/caac.21660. Epub ahead of print. PMID: 33538338.

Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, Bray F. Cancer statistics for the year 2020: An overview. Int J Cancer. 2021 Apr 5. doi: 10.1002/ijc.33588. Epub ahead of print. PMID: 33818764.

